Gene therapy in tissue-engineered blood vessels.

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Gene Therapy

Background:

• Cardiovascular disease is a leading cause of death, with over 1 million arterial bypass procedures annually in the US.
• Current bypass surgeries use autologous veins or synthetic grafts, highlighting a need for improved vascular graft options.
• Tissue-engineered vascular grafts offer potential for biological alternatives in bypass surgery.

Purpose of the Study:

• To investigate the efficacy of a novel retroviral gene delivery system for engineered blood vessels.
• To assess the stable incorporation and longevity of delivered genes in endothelial cells of engineered vessels.
• To establish a framework for optimizing engineered vascular grafts through gene therapy.

Main Methods:

• Development and application of a novel retroviral gene delivery system.
• Targeted gene delivery to endothelial cells within developing engineered blood vessels.
• Assessment of gene incorporation stability over 30 days.

Main Results:

• Specific delivery of a target gene to endothelial cells of engineered vessels was achieved.
• Stable gene incorporation into endothelial cells was maintained for over 30 days.
• Demonstrated the utility of retroviral gene delivery for optimizing engineered vessels.

Conclusions:

• The retroviral gene delivery approach is effective for optimizing the biologic phenotype of engineered vessels.
• This technique provides a foundation for testing genes to enhance engineered blood vessel function.
• Enables potential improvements in bypass surgery outcomes through advanced vascular graft technology.